Dr. Leong research focus on investigating the mechanism of action of potent compounds toward developing new anticancer and antidiabetes drugs. His research adopts an in vitro approach using cell-based and enzymatic assays to identify the various cellular pathways modulated by a potent compound. The research outcome is to understand the mechanism of action of the compound, a prerequisite requirement in developing a new drug entity. In addition, he employs metabolomics to evaluate biomarkers in explaining the treatment outcomes or disease progression. International collaboration has geared his research towards cancer stem cells and utilizing zebrafish as an animal model for cancer. It is believed that cancer stem cells is a subset of cells in tumour that drives chemoresistance and relapse in cancer patients. Therefore, strategies to develop new chemotherapy against the subset of cells is of great interest to tackle the problem.

Mohd. Zamin Bin Jumaat is currently working as a professor and head of Civil Engineering Department, Faculty of Engineering, University of Malaya. His obtained a PhD on structural engineering from University of Southampton, UK. In addition to his post as head of department, Mohd. Zamin is also a council and corporate member of the Institution of Engineers Malaysia (IEM), a professional engineer with the Board of Engineers Malaysia (BEM), the head of the Universiti Malaya Research Centre for Innovative Construction Technology, and the co-opted committee member of the Civil and Structural Division of the Institution of Engineers Malaysia.  Mohd. Zamin's research interests are in the area of analysis and design of structures, instrumentations and structural investigations, repair and strengthening.

Dr. Lee-Ling Lim is Professor of Medicine, UM and Head of the Diabetes Care Unit, Universiti Malaya Medical Centre. As a clinician-scientist, her major areas of interest include cardiometabolic medicine and intergenerational diabetes with translational and implementation science components.  Dr. Lim sits on the Working Groups of The Lancet Commission on Diabetes and the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) Precision Medicine in Diabetes Initiative, who provide authoritative resources in tackling the global diabetes epidemic. She recognizes that every person with diabetes and non-communicable disease (NCD) is unique and warrants personalized care. To revolutionize health care, Dr. Lim aims to advance the implementation of Precision Medicine in Diabetes and NCD, taking into account differences in clinical presentation, genes, and lifestyles in Malaysian populations. These have led to several collaborations with the USA, UK, and other Asian countries. She has published in numerous high-impact journals including The Lancet, Nature, Diabetes Care, and Science Bulletin.  Dr. Lim has received several awards including the World’s Top 2% Scientists by Stanford University for 3 consecutive years (2022-2024), the EFSD Albert Renold Fellowship, the USA Endocrine Society Outstanding Abstract Award, and a scholarship funded by the USA NIH National Institute of General Medical Sciences for training in statistical genetics at the University of Washington, USA. She is an Editorial Board Member of several Tier 1 Web of Science-indexed journals (BMC Medicine, Diabetes/Metabolism Research & Reviews, and Diabetes & Metabolism). Dr. Lim is an article reviewer for 29 leading academic journals including the European Heart Journal, Annals of Internal Medicine, Diabetes Care, PLoS Medicine, and European Journal of Preventive Cardiology.